Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. Noronha A, et al. Among authors: sekar a. Cancer Discov. 2022 Nov 2;12(11):2666-2683. doi: 10.1158/2159-8290.CD-22-0111. Cancer Discov. 2022. PMID: 35895872 Free PMC article.
ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma.
Srivastava S, Nataraj NB, Sekar A, Ghosh S, Bornstein C, Drago-Garcia D, Roth L, Romaniello D, Marrocco I, David E, Gilad Y, Lauriola M, Rotkopf R, Kimchi A, Haga Y, Tsutsumi Y, Mirabeau O, Surdez D, Zinovyev A, Delattre O, Kovar H, Amit I, Yarden Y. Srivastava S, et al. Among authors: sekar a. Cell Rep. 2019 Oct 1;29(1):104-117.e4. doi: 10.1016/j.celrep.2019.08.088. Cell Rep. 2019. PMID: 31577941 Free PMC article.
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.
Haga Y, Marrocco I, Noronha A, Uribe ML, Nataraj NB, Sekar A, Drago-Garcia D, Borgoni S, Lindzen M, Giri S, Wiemann S, Tsutsumi Y, Yarden Y. Haga Y, et al. Among authors: sekar a. Cancer Res. 2021 Jul 15;81(14):3862-3875. doi: 10.1158/0008-5472.CAN-20-3555. Epub 2021 May 3. Cancer Res. 2021. PMID: 33941614 Free PMC article.
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR.
Ghosh S, Nataraj NB, Noronha A, Patkar S, Sekar A, Mukherjee S, Winograd-Katz S, Kramarski L, Verma A, Lindzen M, Garcia DD, Green J, Eisenberg G, Gil-Henn H, Basu A, Lender Y, Weiss S, Oren M, Lotem M, Geiger B, Ruppin E, Yarden Y. Ghosh S, et al. Among authors: sekar a. Cell Rep. 2021 May 25;35(8):109181. doi: 10.1016/j.celrep.2021.109181. Cell Rep. 2021. PMID: 34038737 Free PMC article.
TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis.
Uribe ML, Dahlhoff M, Batra RN, Nataraj NB, Haga Y, Drago-Garcia D, Marrocco I, Sekar A, Ghosh S, Vaknin I, Lebon S, Kramarski L, Tsutsumi Y, Choi I, Rueda OM, Caldas C, Yarden Y. Uribe ML, et al. Among authors: sekar a. Sci Signal. 2021 Jun 22;14(688):eabe6156. doi: 10.1126/scisignal.abe6156. Sci Signal. 2021. PMID: 34158398 Free PMC article.
Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.
Nataraj NB, Noronha A, Lee JS, Ghosh S, Mohan Raju HR, Sekar A, Zuckerman B, Lindzen M, Tarcitano E, Srivastava S, Selitrennik M, Livneh I, Drago-Garcia D, Rueda O, Caldas C, Lev S, Geiger T, Ciechanover A, Ulitsky I, Seger R, Ruppin E, Yarden Y. Nataraj NB, et al. Among authors: sekar a. Cell Rep. 2022 Feb 22;38(8):110418. doi: 10.1016/j.celrep.2022.110418. Cell Rep. 2022. PMID: 35196484 Free PMC article.
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, Yarden Y. Marrocco I, et al. Among authors: sekar a. Cell Rep Med. 2023 Aug 15;4(8):101142. doi: 10.1016/j.xcrm.2023.101142. Epub 2023 Aug 8. Cell Rep Med. 2023. PMID: 37557179 Free PMC article.
2024 Update of the RECOVER-Adult Long COVID Research Index.
Geng LN, Erlandson KM, Hornig M, Letts R, Selvaggi C, Ashktorab H, Atieh O, Bartram L, Brim H, Brosnahan SB, Brown J, Castro M, Charney A, Chen P, Deeks SG, Erdmann N, Flaherman VJ, Ghamloush MA, Goepfert P, Goldman JD, Han JE, Hess R, Hirshberg E, Hoover SE, Katz SD, Kelly JD, Klein JD, Krishnan JA, Lee-Iannotti J, Levitan EB, Marconi VC, Metz TD, Modes ME, Nikolich JŽ, Novak RM, Ofotokun I, Okumura MJ, Parthasarathy S, Patterson TF, Peluso MJ, Poppas A, Quintero Cardona O, Scott J, Shellito J, Sherif ZA, Singer NG, Taylor BS, Thaweethai T, Verduzco-Gutierrez M, Wisnivesky J, McComsey GA, Horwitz LI, Foulkes AS; RECOVER Consortium. Geng LN, et al. JAMA. 2024 Dec 18. doi: 10.1001/jama.2024.24184. Online ahead of print. JAMA. 2024. PMID: 39693079
254 results